Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

Features

IAVI statement on PrEPVacc trial

December 6, 2023

Trial will stop vaccinations due to lack of efficacy.

Read more

Features

The moment is now: navigating the path to TB vaccine success at the Union Conference and beyond

December 6, 2023

This year’s Union Conference set the scene for what could be the biggest year to date for tuberculosis (TB) vaccines.

Read more

Videos

What are VSV vaccines?

December 5, 2023

Watch this video to learn more about VSV vaccines and how they work in the human body.VSV is the same platform technology IAVI and our collaborators are using to develop vaccines for hemorrhagic fever viruses such as Marburg, Lassa, and Ebola Sudan.

Read more

Antibodies for HIV prevention

IAVI and partners are applying their expertise gained from HIV vaccine research to produce what could be a breakthrough in the fight against HIV/AIDS: an injection of bnAbs to prevent HIV infection.

Read more

MTBVAC: the only live-attenuated Mtb vaccine in development

IAVI is partnering with the Spanish biopharmaceutical company Biofabri in the advanced clinical development of the MTBVAC vaccine candidate to see if it prevents TB disease in infants, adolescents, and adults. MTBVAC is the only live, attenuated vaccine candidate derived from M.tb.

Read more

In The News

Céspedes: “HIV treatments have saved many lives”

La Tribuna de Albacete

December 2, 2023

Read more

Features

This World AIDS Day, celebrating community leadership

December 1, 2023

“Science, when it is inclusive, becomes a powerful tool for change,” says IAVI’s Monica Kuteesa.

Read more

IAVI Report

Will AI crack the code for antigens?

November 30, 2023

The scientific implications of artificial intelligence loom large. One tangible application is designing better vaccines.

Read more